Analysis of Plasma for Diagnosis and Follow-up of Neurofibromatosis Type 1

Neurofibromatosis 1 Clinical Trial

Official title:

Analysis of Plasma for Diagnosis and Follow-up of Neurofibromatosis Type 1

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT02680431
• Other study ID #: 141-1801-2015
• Status: Enrolling by invitation
• Phase: N/A
• First received: January 15, 2016
• Last updated: February 8, 2016
• Start date: January 2016
• Est. completion date: December 2020

Study information

• Verified date: February 2016
• Source: Turku University Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Finland: Ethics Committee
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to find blood plasma based biomarkers of disease progression in neurofibromatosis type 1 (NF1). NF1 is associated with the development of benign cutaneous tumors as well as a variety of malignancies. Analysis of plasma DNA and chemical composition may provide tools for diagnosis and follow-up of NF1. The hypothesis of the study is that NF1-associated tumor burden and malignant transformation of tumors can be detected in plasma. To test this hypothesis, Finnish patients with NF1 are recruited and blood sample is taken. Blood plasma is separated and analyzed chemically. DNA is then also extracted and quantified.

Description:

Neurofibromatosis type 1 (NF1) is a dominant hereditary multiorgan disease that causes both benign cutaneous neurofibromas and malignant tumors. Timely detection of malignant transformation in NF1 tumors is of great clinical importance. Also methods to easily monitor individual's overall tumor burden would be useful. Blood plasma is collected from NF1 patients and age- and gender-matched controls. The samples are stored at -80 C until analysis. Free circulating plasma DNA is extracted and quantified using commercial reagents. Also a previously described chemical detection method to observe overall changes in plasma composition is utilized. The analysis results are compared between NF1 patients and healthy controls, and also correlated with NF1 tumor burden and diagnosis of malignancy during five-year follow-up.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 100
• Est. completion date: December 2020
• Est. primary completion date: December 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Finnish-speaking

• 18-85 years old

• For NF1 group: Diagnosis of type 1 neurofibromatosis and visit to Turku Neurofibromatosis Centre

• For control group: Suitable as an age- and gender-matched control for some of the NF1 patients

Exclusion Criteria:

• Non-Finnish-speaking

• For control group: diagnosis of neurofibromatosis type 1 or cancer

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Neurofibroma
• Neurofibromatoses
• Neurofibromatosis 1

Intervention

Other:
• Blood sample
10 mL venous blood sample for analysis of plasma

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Juha Peltonen

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Ability of free circulating plasma DNA concentration and unspecific chemical detection method to predict overall tumor burden	Tumor burden assessed by clinician on a four-level scale: 1 = 0-5 neurofibromas, 2 = 6-99 neurofibromas, 3 = 100-500 neurofibromas, 4 = over 500 neurofibromas	Up to 5 years	No
Primary	Ability of free circulating plasma DNA concentration and unspecific chemical detection method to predict clinical diagnosis of malignancy	Information on clinical diagnoses is obtained from patient records	Up to 5 years	No